3 years ago

52 North Health Secures £1 Million to Trial Sepsis Testing Device

  • 52 North Health, a UK-based medtech startup, has raised £1 million in its first funding round led by Cambridge Enterprise

  • The funding will be used to conduct clinical trials for its NeutroCheck device, which uses AI to determine the risk of neutropenic sepsis for patients undergoing chemotherapy

  • The device allows patients to monitor their risk at home through a blood finger-prick

  • The company also plans to partner with the UK Sepsis Trust and Macmillan Cancer Support

  • 52 North Health aims to improve healthcare by providing a more accurate and timely diagnosis of neutropenic sepsis, which can lead to faster treatment and better outcomes for patients.

      • ProblemHealthcare

      "Currently, patients going through chemotherapy who feel unwell are told to go to A&E, where patients are given antibiotics and blood tests, however, half are found to have no risk."

      Solution

      "52 North Health is developing a portable device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. The device allows patients to determine their risk at home through a blood finger-prick, reducing unnecessary trips to the hospital and antibiotic use."

      Covered on